Dexamethasone for the treatment of class I HELLP syndrome: A double-blind, placebo-controlled, multicenter, randomized clinical trial

Dexamethasone for the treatment of class I HELLP syndrome: A double-blind, placebo-controlled, multicenter, randomized clinical trial

•Dexamethasone does not decrease the hospital stay in women with HELLP syndrome 1.•Dexamethasone does not improve the time to recovery of platelets in women with HELLP syndrome 1.•Dexamethasone does not reduce the risk of maternal complications in women with HELLP syndrome 1.•Studies with a larger s...

Full description

Saved in:
Bibliographic Details
Published in:Pregnancy hypertension Vol. 17; pp. 158 - 164
Main Authors: Fonseca, Javier E., Otero, Juan C, Messa, Clara
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01-07-2019
Subjects:
Adult
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Colombia
Dexamethasone - administration & dosage
Dexamethasone - therapeutic use
Double-Blind Method
Female
HELLP Syndrome - blood
HELLP Syndrome - drug therapy
HELLP Syndrome - physiopathology
Humans
Pregnancy
Pregnancy Outcome
Prenatal Care
Treatment Outcome
Young Adult
Colombia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Dexamethasone does not decrease the hospital stay in women with HELLP syndrome 1.•Dexamethasone does not improve the time to recovery of platelets in women with HELLP syndrome 1.•Dexamethasone does not reduce the risk of maternal complications in women with HELLP syndrome 1.•Studies with a larger sample size are required to have conclusions regarding the efficacy of dexamethasone in HELLP syndrome 1.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:2210-7789
2210-7797
DOI:10.1016/j.preghy.2019.06.003